DCTH Delcath Systems Inc.

0.06
-0.02  -29%
Previous Close 0.08
Open 0.06
Price To book 45.93
Market Cap 28195266
Shares 499,031,259
Volume 44,744,797
Short Ratio 0.83
Av. Daily Volume 63,183,105

SEC filingsSee all SEC filings

  1. PRE 14C - Other preliminary information statements 171096243
  2. 8-K - Current report 171096222
  3. 8-K - Current report 171095487
  4. 8-K - Current report 171083448
  5. 8-K - Current report 171067618

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

No data release timeline given by company. Estimated completion date was June 2016 as per information supplied by company to clinicaltrials.gov. Note that the company has not updated the enrollment status on clinicaltrials.gov since March 2015.
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
CRL issued September 13, 2013. New Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer

SEC Filings

  1. PRE 14C - Other preliminary information statements 171096243
  2. 8-K - Current report 171096222
  3. 8-K - Current report 171095487
  4. 8-K - Current report 171083448
  5. 8-K - Current report 171067618
  6. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171067612
  7. 8-K - Current report 171053238
  8. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171053234
  9. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171044248
  10. 8-K - Current report 171043276